An independent reference library on stem cell therapy and cancer immunotherapy research.
247 articles · 2 topics · 162 Stem Cell Research · 85 Cancer Immunotherapy
Step 1 — Topic
Step 2 — Category
All 247 articles
Small human studies of adipose-derived and placental stem cells show shrinking plaques and less distress in Peyronie's disease, but the best trial missed its curvature goal and nothing is FDA-approved.
Lab studies and a small case series suggest mesenchymal stem cells may calm hidradenitis suppurativa inflammation and help stubborn tunnels heal — but the approach is experimental and not FDA-approved.
Stem cell therapies move through a funding relay — NIH and state grants, universities, foundations, then venture capital. Legitimate trials don't charge patients for the experimental product.
The FDA's 2024 class-wide boxed warning on secondary T-cell cancers after CAR-T flagged a real signal — but the largest datasets since show the absolute risk is low and CAR-T's benefits still outweigh it.
Most pancreatic tumors are genetically quiet and walled off by dense stroma, so checkpoint inhibitors rarely work — except in the small MSI-H/dMMR subset. Personalized mRNA vaccines are the most promising lead.
Randomized trials of fat-derived stem cell injections into the jaw joint beat hyaluronic acid on pain and mouth opening — but the evidence base is small and rated weak.
Mesenchymal stem cells and their vesicles reduce liver fat and fibrosis in animal models — but there is still no completed human trial in NAFLD or NASH specifically.
Gene and cell therapies reach approval roughly 10–17% of the time. Here's why late-stage failure is common, what causes it, and how to read trial news carefully.
An off-the-shelf CD7-targeted CAR-T produced a 91% response rate in evaluable Phase 1 patients — in cancers with no new FDA-approved therapy since 2005.
All six FDA-approved CAR-T products are made from the patient's own cells. Off-the-shelf donor CAR-T is faster and cheaper in theory — and still investigational.
Pooled randomized trial data show a real but modest pain-relief signal from intradiscal MSC injection — alongside a primary-endpoint miss in the largest pivotal program.
Pooled trial data link stem cell therapy to higher ulcer healing and lower amputation rates — but the trials are small, and no product is FDA-approved for this use.
Every feature article on regenmedreview carries a Sources block listing its references. Where the original source material included no external citations, that is stated explicitly rather than left blank.